Investment Type: Venture Capital; Accelerator
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 10.01.2026 | EpiBiologi... | epibiologics.com | $157M | United Sta... |
Mentions in press and media 4
| Date | Title | Description |
| 11.01.2026 | EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity | EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate... |
| 10.01.2026 | EpiBiologics: $107 Million Series B Raised To Advance Tissue-Selective EGFR Degrader And Bispecific Antibody Pipeline | EpiBiologics announced it has closed a $107 million Series B financing to advance a pipeline of bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. The round was co-led by GV and J... |
| 08.01.2026 | EpiBiologics Closes $107M Series B Funding | EpiBiologics, a San Mateo, CA-based company which specializes in tissue-selective extracellular protein degradation, raised $107M in Series B funding. The round was co-led by GV (Google Ventures) and Johnson & Johnson, through its corpo... |
| 07.09.2022 | Roche shells out $250M to acquire Good Therapeutics and its preclinical oncology program | Roche announced Wednesday that it is paying $250 million in cash to acquire Good Therapeutics, a Seattle-based preclinical biotech company. Good has raised a little over $30 million since it was founded in 2016. The company is focused on cy... |